Types of Retinoblastoma

Retinoblastoma is a rare cancer that starts in the retina, which is the light-detecting layer at the back of the eye. It most often affects young children, usually under the age of five. In simple terms, imagine the retina as the film in an old-style camera—when some of its cells grow without stopping and form a tumor, that’s retinoblastoma. Because it can grow quickly, early detection is vital to save both life and vision Cancer.org.

Retinoblastoma is a rare but serious eye cancer that begins in the retina, the light-sensing tissue at the back of the eye. It most commonly affects children under three years old, with about 80% of cases diagnosed by age three Wikipedia. This tumor arises when both copies of the RB1 gene—which normally help control cell growth—are mutated, allowing immature retinal cells to multiply unchecked Wikipedia. Early signs include a white glow in the pupil (leukocoria), crossed eyes (strabismus), poor vision, or eye redness. Without treatment, retinoblastoma can spread within the eye, into the brain, or elsewhere in the body, making prompt diagnosis and therapy vital.

---

Types of Retinoblastoma

Retinoblastomas are generally classified by how they arise and how they appear:

1. Heritable (Germline) Retinoblastoma

   • Caused by an inherited (germline) mutation of the RB1 tumor suppressor gene.

   • Children with this type often develop tumors in both eyes (bilateral) and may pass the mutation to future children. Each child of a parent with heritable retinoblastoma has a 50% chance of inheriting the mutation NCBI.

2. Non-Heritable (Sporadic) Retinoblastoma

   • Occurs when two mutations happen by chance in the same retinal cell during early development.

   • Usually presents as a tumor in one eye only (unilateral). About 60% of cases are non-heritable Canadian Cancer Society.

3. Unilateral vs. Bilateral

   • Unilateral: Tumor in one eye (more common in non-heritable cases).

   • Bilateral: Tumors in both eyes (hallmark of heritable cases).

4. Trilateral Retinoblastoma

   • A rare form in which, in addition to eye tumors, a midline brain tumor (most often in the pineal gland) develops.

   • Almost always seen in children with heritable retinoblastoma and carries a poorer prognosis without early detection WikipediaRadiopaedia.

---

Causes (Risk Factors and Genetic Mechanisms)

While retinoblastoma itself is driven by mutations in specific genes, there are many genetic mechanisms and risk factors that can lead to those mutations. Below are 20 recognized causes or contributors:

1. Germline RB1 Mutation

   • A faulty RB1 gene inherited from a parent causes every cell to carry one altered copy.

2. Somatic RB1 Mutation

   • Two separate “spontaneous” mutations occur in a single retinal cell during fetal development.

3. Loss of Heterozygosity (LOH)

   • The normal RB1 gene copy is lost, leaving only the mutated one.

4. Chromosome 13q14 Deletion

   • A large piece of chromosome 13, including RB1, is missing.

5. Point Mutations in RB1

   • Small changes (one letter) in the DNA code that inactivate RB1.

6. Splice-Site Mutations

   • Errors in the RNA-processing sites of RB1, leading to an abnormal protein.

7. Nonsense Mutations in RB1

   • A “stop” signal appears too soon, truncating the RB1 protein.

8. Frameshift Mutations in RB1

   • Insertions or deletions shift the reading frame, making the protein nonfunctional.

9. Promoter Hypermethylation

   • Chemical tags silence RB1 gene expression without changing its DNA sequence.

10. Epigenetic Silencing

    • Other chemical changes on DNA or histones block RB1 activity.

11. MYCN Gene Amplification

    • Rare cases (<2%) where high copy numbers of the MYCN oncogene drive tumor growth without RB1 loss PMC.

12. Parental Mosaicism

    • A parent carries the mutation in some cells only, passing it to the child unexpectedly.

13. Advanced Paternal Age

    • Slightly increased risk of new (de novo) mutations in sperm.

14. In Vitro Fertilization (IVF)

    • Some studies suggest a small association, possibly due to underlying infertility issues.

15. Radiation Exposure In Utero

    • Extremely rare; high-dose radiation to the mother’s abdomen can induce mutations.

16. Chemical Exposures

    • No strong proven links, but very high exposures to certain mutagens could theoretically increase risk.

17. Inherited Cancer Syndromes

    • Rare overlap with other syndromes that affect DNA repair, e.g., Li-Fraumeni syndrome.

18. Chromosomal Rearrangements

    • Translocations or inversions disrupt RB1 regulatory regions.

19. Cytogenetic Abnormalities

    • Complex chromosomal changes that indirectly inactivate RB1.

20. Random Developmental Errors

    • Mistakes during the rapid cell division of early eye formation can lead to two hits in RB1.

---

Symptoms

Retinoblastoma may present with various eye-related signs. Early detection often comes from noticing one of the following:

1. Leukocoria (White Pupil Reflex)

   • The pupil appears white instead of red in flash photographs Verywell Health.

2. Strabismus (Crossed Eyes)

   • Eyes that do not look in the same direction at the same time.

3. Poor Vision

   • Child doesn’t respond to visual cues or seems not to see well.

4. Red or Irritated Eye

   • Chronic redness without infection signs.

5. Eye Pain

   • Rubbing, tearing, or apparent discomfort around the eye.

6. Glaucoma-Like Symptoms

   • Increased pressure inside the eye causing pain and redness.

7. Bulging Eye (Proptosis)

   • Visible swelling of the eyeball.

8. Hyphema

   • Blood in the front chamber of the eye.

9. Nystagmus

   • Rapid, involuntary eye movements.

10. Heterochromia Iridis

    • One iris (colored part) looks different in shade or color.

11. Ocular Inflammation

    • Swelling of tissues around the eye socket.

12. Enophthalmos

    • Sunken appearance of the eyeball (in advanced or extraocular disease).

13. Persistent Eye Irritation

    • Rubbing eyes, fussiness in infants.

14. Photophobia

    • Sensitivity to light, causing squinting or tears.

15. Facial Asymmetry

    • Swelling or mass effect altering normal facial appearance.

---

Diagnostic Tests

Accurate diagnosis combines many approaches. Below they are grouped by type:

A. Physical Exam

1. Visual Acuity Test

   • Measures how well a child can see at various distances.

2. Intraocular Pressure Measurement

   • Checks for glaucoma-like high eye pressure.

3. Slit-Lamp Examination

   • Uses a microscope with a bright light to view the front of the eye.

4. Dilated Fundus Examination

   • Drops dilate the pupil so the doctor can inspect the retina.

5. Red Reflex Test

   • A light shines through the pupil; absence or change of red reflex suggests a mass Wikipedia.

B. Manual Tests

6. Hirschberg Corneal Light Reflex Test

   • Checks if the reflection of a light on the corneas is symmetrical.

7. Cover-Uncover Test

   • Identifies misalignment by covering one eye.

8. Ocular Palpation

   • Gently pressing around the eye socket to feel for masses.

9. Fundus Photography

   • Taking pictures of the retina to document tumor size and location.

C. Lab and Pathological Tests

10. Histopathology of Enucleated Tissue

    • Microscopic examination of removed eye tissue.

11. RB1 Gene Sequencing

    • DNA testing for mutations in the RB1 gene.

12. Methylation Analysis

    • Checks promoter silencing of RB1.

13. Fluorescence In Situ Hybridization (FISH)

    • Detects large deletions or rearrangements of RB1.

14. Polymerase Chain Reaction (PCR) for MYCN

    • Identifies MYCN amplification in rare non-RB1 tumors PMC.

D. Electrodiagnostic Tests

15. Electroretinography (ERG)

    • Measures electrical responses of the retina to light.

16. Visual Evoked Potential (VEP)

    • Records brain waves in response to visual stimuli.

17. Electro-oculography (EOG)

    • Evaluates the function of the retinal pigment epithelium.

E. Imaging Tests

18. Ocular Ultrasound (B-scan)

    • Sound waves outline the tumor’s size and shape Cancer.org.

19. Magnetic Resonance Imaging (MRI)

    • Detailed pictures of the eye, optic nerve, and brain UT Southwestern Medical Center.

20. Computed Tomography (CT) Scan

    • Less used due to radiation but can show calcifications within the tumor.

Non-Pharmacological Treatments

Focal and radiation therapies aim to destroy tumor cells locally without systemic drugs.

1. Cryotherapy
   A cryoprobe freezes the tumor through the white of the eye, causing ice-crystal formation in cancer cells. It’s best for small, peripheral tumors under 4 disc diameters, either alone or after chemotherapy to consolidate shrinkage Cancer.govPMC.

2. Laser Photocoagulation
   Focused laser light coagulates blood vessels feeding the tumor, starving it of oxygen. Used for small posterior tumors after chemoreduction, it leaves a pale scar and is repeated as needed PMCCancer.org.

3. Thermotherapy
   Infrared heat (usually from a diode or xenon laser) warms the tumor to about 45 °C, damaging proteins and killing cells. It often complements chemotherapy for Group A and B eyes to improve local control PMC+1.

4. Planned Plaque Brachytherapy
   A radioactive plaque (often iodine-125) is sutured to the sclera over the tumor, delivering high-dose radiation directly to cancer cells while sparing surrounding tissue. Ideal for solitary, medium-sized tumors PMCCancer.org.

5. External Beam Radiotherapy (EBRT)
   High-energy X-rays target the entire orbit or optic nerve. Used rarely now—only for refractory or extraocular disease—due to long-term risks of secondary cancers in hereditary cases PMCCancer.org.

6. Transpupillary Thermotherapy (TTT)
   A special infrared laser passes through the pupil to heat the tumor from within, suitable for very small central tumors. It’s less invasive than plaque therapy but may require multiple sessions AetnaPMC.

7. Stereotactic Radiosurgery (e.g., Gamma Knife)
   Precisely focused beams converge on the tumor, minimizing exposure to healthy tissue. Reserved for eyes that fail other focal treatments or with limited extraocular spread.

8. Proton Beam Therapy
   Uses charged protons that stop at a precise depth, reducing radiation beyond the tumor. Investigational in retinoblastoma but promising for salvage in selected cases.

9. Focal Ultrasound Hyperthermia
   High-intensity focused ultrasound heats the tumor noninvasively, potentially damaging cells and enhancing chemotherapy uptake. Still experimental.

10. Photodynamic Therapy (PDT)
    A light-activated drug (e.g., verteporfin) localizes in tumor cells; near-infrared light then activates it to produce reactive oxygen species that kill cancer cells. Limited data in retinal tumors.

Additional supportive “therapies and others” help children cope with diagnosis and preserve function:

11. Vision Rehabilitation
    Low-vision specialists train children and families in using remaining sight, fitting magnifiers or adaptive devices to maximize vision.

12. Genetic Counseling
    Families learn about hereditary risk, implications for future children, and need for regular eye exams in siblings.

13. Psychosocial Support
    Child life therapists and psychologists help children and parents manage anxiety, fear, and adjustment to treatments.

14. Occupational Therapy
    Helps children develop fine-motor skills and adapt activities to vision deficits.

15. Physical Therapy
    Addresses any balance or coordination issues following treatment.

16. Pain Management (Non-Drug)
    Techniques like guided imagery, massage, or acupuncture can reduce procedural pain and anxiety Cancer.govPMC.

17. Nutritional Counseling
    Ensures adequate growth and healing support, focusing on balanced intake of proteins, vitamins, and calories.

18. Complementary Therapies
    Meditation, yoga, or art therapy improve coping skills and quality of life when used alongside medical treatment TIME.

19. Support Groups
    Connecting families with others facing retinoblastoma provides emotional comfort and practical advice.

20. Regular Eye Screening
    After treatment, children undergo frequent exams (initially every 2–4 weeks) to detect recurrence early.

---

Drug Treatments

Systemic and local chemotherapy regimens are the backbone of globe-sparing therapy.

1. Carboplatin

   • Class: Platinum-based alkylating agent

   • Dosage: 560 mg/m² IV, Days 1–2 of each 28-day cycle

   • Schedule: Every 3–4 weeks, 4–6 cycles

   • Purpose: Shrink intraocular tumors before focal therapy

   • Mechanism: Crosslinks DNA, blocking replication Cancer.org

   • Side Effects: Myelosuppression, nephrotoxicity, ototoxicity

2. Vincristine

   • Class: Vinca alkaloid

   • Dosage: 1.5 mg/m² IV on Day 1 of each cycle

   • Schedule: Often combined with carboplatin and etoposide

   • Purpose: Inhibit mitosis in dividing tumor cells

   • Mechanism: Binds tubulin, preventing microtubule formation PMC

   • Side Effects: Neurotoxicity, constipation

3. Etoposide

   • Class: Topoisomerase II inhibitor

   • Dosage: 150 mg/m² IV, Days 1–2 of each cycle

   • Purpose: Prevent DNA strand rejoining, causing cell death

   • Mechanism: Inhibits topoisomerase II PMC

   • Side Effects: Myelosuppression, alopecia, mucositis

4. Cisplatin

   • Class: Platinum compound

   • Dosage: 90 mg/m² IV on Day 1

   • Purpose: Alternative platinum agent if carboplatin resistance

   • Mechanism: DNA crosslinking

   • Side Effects: Severe nausea, nephrotoxicity, ototoxicity

5. Cyclophosphamide

   • Class: Alkylating agent

   • Dosage: 1 g/m² IV on Day 1

   • Purpose: Additional systemic control in high-risk or metastatic cases

   • Mechanism: Inactivates DNA via alkylation

   • Side Effects: Hemorrhagic cystitis, myelosuppression

6. Topotecan

   • Class: Topoisomerase I inhibitor

   • Dosage: 1 mg/m² IV, Days 1–5 of each cycle

   • Purpose: Used in intra-arterial or systemic regimens for vitreous seeds

   • Mechanism: Inhibits topoisomerase I

   • Side Effects: Myelosuppression, diarrhea

7. Melphalan (Intravitreal/Intra-arterial)

   • Class: Nitrogen mustard alkylator

   • Dosage: 20–30 µg intravitreal; 5 mg for intra-arterial infusion

   • Purpose: Directly treat vitreous seeds that resist systemic chemo

   • Mechanism: Crosslinks DNA, inducing apoptosis

   • Side Effects: Ocular toxicity (cataract, retinopathy)

8. Doxorubicin

   • Class: Anthracycline

   • Dosage: 25 mg/m² IV, Day 1

   • Purpose: Rarely used in salvage regimens

   • Mechanism: Intercalates DNA and generates free radicals

   • Side Effects: Cardiotoxicity, myelosuppression

9. Ifosfamide

   • Class: Alkylating agent

   • Dosage: 1.8 g/m² IV, Days 1–5

   • Purpose: Salvage therapy in advanced or extraocular disease

   • Mechanism: DNA crosslinking

   • Side Effects: Neurotoxicity, hemorrhagic cystitis

10. Cyclophosphamide + Vincristine + Etoposide (CVE)

• Schedule: Multi-drug combination over 6 cycles

• Purpose: High-risk or metastatic retinoblastoma

• Mechanism: Synergistic DNA damage and mitotic inhibition

• Side Effects: Combined myelosuppression, gastrointestinal upset

---

Dietary Molecular & Herbal Supplements

Note: None replace standard therapy. Always discuss supplements with your oncologist.

1. Curcumin (Turmeric extract)

   • Dosage: 500–1,000 mg daily

   • Function: Anti-inflammatory, antioxidant

   • Mechanism: Inhibits NF-κB signaling, may induce cancer cell apoptosis

2. Epigallocatechin Gallate (EGCG, green tea)

   • Dosage: 200–400 mg daily

   • Function: Antioxidant, anti-angiogenic

   • Mechanism: Blocks VEGF, hindering tumor blood supply

3. Resveratrol (Grapes, berries)

   • Dosage: 150–500 mg daily

   • Function: Anti-proliferative

   • Mechanism: Activates p53 pathway, may trigger cancer cell death

4. Melatonin

   • Dosage: 3–10 mg at bedtime

   • Function: Regulates sleep, potential cancer-cell sensitizer

   • Mechanism: Modulates apoptotic proteins, antioxidant effects

5. All-trans Retinoic Acid (Vitamin A)

   • Dosage: 10,000–25,000 IU daily

   • Function: Supports cell differentiation

   • Mechanism: Binds retinoic acid receptors, may suppress tumor growth

6. Vitamin D3

   • Dosage: 1,000–2,000 IU daily

   • Function: Immune modulation

   • Mechanism: Activates Vitamin D receptor, may inhibit proliferation

7. Quercetin

   • Dosage: 500 mg daily

   • Function: Antioxidant, anti-inflammatory

   • Mechanism: Inhibits tyrosine kinases in cancer cells

8. Sulforaphane (Broccoli sprout extract)

   • Dosage: 30–60 mg daily

   • Function: Detoxification support

   • Mechanism: Upregulates phase II enzymes, may inhibit carcinogenesis

9. Lycopene

   • Dosage: 10–20 mg daily

   • Function: Antioxidant

   • Mechanism: Scavenges free radicals, may reduce DNA damage

10. Selenium

• Dosage: 100–200 µg daily

• Function: Antioxidant enzyme cofactor

• Mechanism: Supports glutathione peroxidase, may lower mutation rates

11. Zinc

• Dosage: 15–30 mg daily

• Function: DNA repair, immune support

• Mechanism: Cofactor for DNA-repair enzymes

12. Omega-3 Fatty Acids

• Dosage: 1–2 g EPA/DHA daily

• Function: Anti-inflammatory

• Mechanism: Alters cell membrane composition, may reduce tumor spread

13. Green Coffee Bean Extract

• Dosage: 200–400 mg daily

• Function: Antioxidant

• Mechanism: Chlorogenic acids scavenge free radicals

14. Alpha-lipoic Acid

• Dosage: 300–600 mg daily

• Function: Antioxidant recycling

• Mechanism: Regenerates vitamins C and E, protects cells

15. Probiotics

• Dosage: 1–10 billion CFU daily

• Function: Gut health, immune modulation

• Mechanism: Balances microbiome, may reduce inflammation

---

Advanced Immunotherapy & Regenerative Drugs

Most are experimental in retinoblastoma; used in clinical trials.

1. GD2-CAR T Cells

   • Dose: ~1×10⁶ CAR T cells/kg IV or local

   • Function: Direct killing of GD2-expressing tumor cells

   • Mechanism: Patient T cells engineered to target GD2 antigen PMC.

2. GPC2-CAR T Cells

   • Dose: Clinical trial doses vary (~1×10⁶–10⁷ cells/kg)

   • Function: Target GPC2 on retinoblastoma and CNS metastases

   • Mechanism: CAR T cells recognize GPC2, inducing tumor apoptosis AACR Journals.

3. Pembrolizumab (Keytruda®)

   • Dose: 2 mg/kg IV every 3 weeks

   • Function: Checkpoint inhibitor for refractory cases

   • Mechanism: Blocks PD-1/PD-L1, boosting T-cell attack MDPI.

4. Oncolytic Virus (DNX-2401)

   • Dose: Intratumoral injections per trial protocol

   • Function: Selective replication in tumor cells

   • Mechanism: Virus lyses cancer cells and recruits immune response.

5. Alisertib + Pembrolizumab

   • Dose: Alisertib 50 mg BID; Pembrolizumab 2 mg/kg Q3W

   • Function: Overcomes immunotherapy resistance

   • Mechanism: Aurora kinase A inhibition sensitizes tumors to PD-1 blockade PubMed.

6. High-Dose Chemo + Stem Cell Transplant

   • Procedure Dose: Myeloablative chemo followed by autologous SCT

   • Function: Rescue bone marrow after intensive therapy

   • Mechanism: Eliminates resistant clones; restores hematopoiesis Canadian Cancer Society.

---

Surgeries

Surgical removal remains essential when focal therapies fail or disease is advanced.

1. Enucleation

   • Procedure: Complete removal of the eye and part of the optic nerve

   • Why: Curative for eyes with large tumors (Group E) or extensive vitreous seeds; prevents spread Wikipedia.

2. Orbital Exenteration

   • Procedure: Removal of the eye plus eyelids and orbital contents

   • Why: Reserved for extraocular extension when globe-preserving options are exhausted.

3. Orbital Biopsy with Local Debulking

   • Procedure: Tissue sampling and partial tumor removal

   • Why: Rarely done; only if diagnosis is uncertain and vision salvage is impossible.

4. Secondary Ocular Prosthesis Placement

   • Procedure: Fitting of artificial eye after enucleation

   • Why: Cosmetic rehabilitation and socket health.

5. Vitrectomy-Guided Intravitreal Injection

   • Procedure: Surgical tap and injection of chemotherapy into the vitreous

   • Why: Directly treats persistent vitreous seeds under surgical visualization.

---

Preventions

While hereditary cases cannot be prevented, early detection and risk reduction are possible.

1. Newborn Red-Reflex Screening

2. Sibling Eye Exams Every 3–6 Months (for heritable cases)

3. Genetic Testing for RB1 Mutations

4. Prenatal Genetic Counseling

5. Avoid Radiation Exposure During Pregnancy

6. Prompt Referral for Any White Pupil Glow

7. Education of Pediatricians on Early Signs

8. Public Awareness Campaigns in High-Risk Regions

9. Neonatal Ophthalmology Access in Underserved Areas

10. Regular Eye Exams in Children with Familial History

---

When to See a Doctor

Seek evaluation immediately if a child’s eye appears white in photos, if one eye turns inward or outward, if vision seems poor, or if there’s unexplained eye redness or swelling. Early referral to a pediatric ophthalmologist can be sight- and life-saving.

---

Dietary Do’s and Don’ts

Do:

1. Eat colorful fruits and vegetables (antioxidants)

2. Include lean proteins (for healing)

3. Consume whole grains (fiber for gut health)

4. Hydrate adequately (support chemo clearance)

5. Add sources of omega-3s (anti-inflammation)

6. Incorporate probiotics (gut-immune axis)

7. Take vitamin supplements only as prescribed

8. Choose low-sodium foods (reduce fluid retention)

9. Snack on nuts and seeds (healthy fats)

10. Maintain regular meal times (support growth)

Don’t:

1. Avoid unpasteurized dairy (infection risk)

2. Skip raw or undercooked meats (infection risk)

3. Limit sugary snacks (excess calories, no nutrients)

4. Avoid grapefruit (drug interactions)

5. Don’t overuse herbal teas (unregulated potency)

6. Minimize processed foods (low nutrient density)

7. Limit high-iron foods without monitoring (chemo interactions)

8. Avoid alcohol entirely (contraindicated in children)

9. Don’t use unverified supplements (safety concerns)

10. Skip meals during treatment days (energy needs high)

---

Frequently Asked Questions

1. What causes retinoblastoma?
   Mutations in the RB1 gene cause retinal cells to grow uncontrollably.

2. Is retinoblastoma hereditary?
   About 40% of cases are hereditary; children inherit one mutated RB1 gene.

3. Can retinoblastoma be cured?
   Yes—over 95% cure rate in high-income countries with early treatment.

4. Will my child lose vision?
   Many eyes retain useful vision after focal therapies, though severe cases may need enucleation.

5. How long is treatment?
   Typically 4–6 months for chemotherapy plus ongoing focal therapies.

6. Is chemotherapy painful?
   IV chemo can cause discomfort; anti-nausea and pain meds help manage side effects.

7. Can retinoblastoma spread?
   If untreated, it can invade the brain or bone marrow; early therapy prevents spread.

8. What follow-up is needed?
   Exams every 2–4 weeks initially, then spaced out over years to watch for new tumors.

9. Are second cancers a risk?
   Hereditary cases have up to a 50% risk of other cancers later; regular screening is essential.

10. Will my child be normal?
    Most survivors lead healthy lives; psychosocial support aids adjustment.

11. Can siblings be tested?
    Yes—genetic testing and regular eye exams are recommended.

12. Is radiation safe?
    Focal plaque therapy has lower risk; EBRT is avoided in hereditary cases due to second-cancer risk.

13. Are natural therapies helpful?
    Supplements like antioxidants may support health but never replace standard care.

14. How is vision measured?
    Pediatric ophthalmologists use age-appropriate tests (fixation, tracking, Teller acuity cards).

15. Where to get more info?
    Reputable sources include the American Cancer Society, National Cancer Institute, and Retinoblastoma International Alliance.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 07, 2025.

PDF Document For This Disease Conditions References